Implementation of a Market Entry Reward within the United States

J Law Med Ethics. 2018 Jun;46(1_suppl):50-58. doi: 10.1177/1073110518782915.

Abstract

As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to "value-based" payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Bacterial Agents / economics*
  • Drug Discovery / economics*
  • Drug Resistance, Microbial
  • Health Policy
  • Humans
  • Reward
  • Risk Sharing, Financial
  • United States

Substances

  • Anti-Bacterial Agents